Jie Wang - Concepedia

Author

Jie Wang

Chinese Academy of Medical Sciences & Peking Union Medical College ORCID

Also Known As

David Melvin, Fu, Yunjie, Guangsuo Wang, Hua Bai, J Wang, J. Huag, J. WANG, J. Wang, JIE WANG, JIE Wang

648

Publications

17.6K

Citations

H-Index

166

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College Peking University Peking University Cancer Hospital Sun Yat-sen University Henan Cancer Hospital

About

Jie Wang is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	68	8K
2	Health Sciences	12	13	583
3	Public Health	6	6	234
4	Natural Sciences	5	5	148
5	Engineering	1	1	26

Jie Wang

195

Publications

15.1K

Citations

H-Index

Page 1

	Year	Citations
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel Zhijie Wang, Jianchun Duan, Shangli Cai, JAMA Oncology	2019	491
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa, The Lancet Oncology Chemotherapy Versus PlaceboMedicineFirst-line GefitinibCancer GrowthPathology	2015	404
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC Shugeng Gao, Ning Li, Shun‐Yu Gao, Journal of Thoracic Oncology	2020	399
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer Jie Wang, Shun Lü, Xinmin Yu, JAMA Oncology	2021	381
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Jie Wang, Caicun Zhou, Wenxiu Yao, The Lancet Oncology OncologyPharmacologyBronchial NeoplasmImmune Checkpoint InhibitorFirst-line Treatment	2022	361
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial Roy S. Herbst, Yi‐Long Wu, Thomas John, Journal of Clinical Oncology	2023	350
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial Yi‐Long Wu, Shun Lü, Ying Cheng, Journal of Thoracic Oncology	2019	347
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Yi‐Long Wu, Jin Soo Lee, Sumitra Thongprasert, The Lancet Oncology OncologyMedicineMetronomic TherapyDouble-blind TrialBronchial Neoplasm	2013	304
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer Jiefei Han, Jianchun Duan, Hua Bai, Cancer Immunology Research	2019	266

Page 1